Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke

Ischemic stroke is the most common type of stroke, and early interventional treatment is associated with favorable outcomes. In the guidelines, thrombolytic therapy using recombinant tissue-type plasminogen activator (rt-PA) is recommended for eligible patients with acute ischemic stroke. However, the risk of hemorrhagic complications limits the use of rt-PA, and the risk factors for poor treatment outcomes need to be identified. To identify the risk factors associated with in-hospital poor outcomes in patients treated with rt-PA, we analyzed the electronic medical records of patients who were diagnosed with acute ischemic stroke and treated for rt-PA at Chang Gung Memorial Hospitals from 2006 to 2016. In-hospital death, intensive care unit (ICU) stay, or prolonged hospitalization were defined as unfavorable treatment outcomes. Medical history variables and laboratory test results were considered variables of interest to determine risk factors. Among 643 eligible patients, 537 (83.5%) and 106 (16.5%) patients had favorable and poor outcomes, respectively. In the multivariable analysis, risk factors associated with poor outcomes were female gender, higher stroke severity index (SSI), higher serum glucose levels, lower mean corpuscular hemoglobin concentration (MCHC), lower platelet counts, and anemia. The risk factors found in this research could help us study the treatment strategy for ischemic stroke.

[1]  K. Johnston,et al.  Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke , 2014, Vascular health and risk management.

[2]  A. Alexandrov,et al.  Does the sex of acute stroke patients influence the effectiveness of rt-PA? , 2014, BMC Neurology.

[3]  V. Kostic,et al.  Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study , 2009, Clinical Neurology and Neurosurgery.

[4]  J. Jeng,et al.  Get With The Guidelines-Stroke Performance Indicators: Surveillance of Stroke Care in the Taiwan Stroke Registry: Get With The Guidelines-Stroke in Taiwan , 2010, Circulation.

[5]  M. Tseng,et al.  Safety and Effectiveness of Intravenous Thrombolysis for Acute Ischemic Stroke Outside the Coverage of National Health Insurance in Taiwan. , 2017, Acta neurologica Taiwanica.

[6]  D. Cutler,et al.  Trends in thrombolytic use for ischemic stroke in the United States. , 2010, Journal of hospital medicine.

[7]  H. Horiguchi,et al.  Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator , 2014, Journal of the Neurological Sciences.

[8]  Y. Kao Yang,et al.  National survey of thrombolytic therapy for acute ischemic stroke in Taiwan 2003-2010. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[9]  J. De Keyser,et al.  The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[10]  David Ring,et al.  The Elixhauser Comorbidity Method Outperforms the Charlson Index in Predicting Inpatient Death After Orthopaedic Surgery , 2014, Clinical orthopaedics and related research.

[11]  P. Lapchak.  Critical Early Thrombolytic and Endovascular Reperfusion Therapy for Acute Ischemic Stroke Victims: a Call for Adjunct Neuroprotection , 2015, Translational Stroke Research.

[12]  Sung-Chun Tang,et al.  Intravenous Thrombolysis Administration 3–4.5 h After Acute Ischemic Stroke: A Retrospective, Multicenter Study , 2019, Front. Neurol..

[13]  Andrew E Moran,et al.  Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet. Global health.

[14]  P. Lyden.  Why don’t more patients receive intravenous rt-PA for acute stroke? , 2015, Expert review of neurotherapeutics.

[15]  S. Mayer,et al.  Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2017, Stroke.

[16]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[17]  D. Liebeskind,et al.  Unfavorable neurological outcome in diabetic patients with acute ischemic stroke is associated with incomplete recanalization after intravenous thrombolysis , 2015, Journal of NeuroInterventional Surgery.

[18]  T. Tatlisumak,et al.  Does Sex Influence the Response to Intravenous Thrombolysis in Ischemic Stroke?: Answers From Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register , 2013, Stroke.

[19]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[20]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[21]  Sheng-Feng Sung,et al.  Code stroke: a mismatch between number of activation and number of thrombolysis. , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  Yilong Wang,et al.  Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild Stroke , 2017, Scientific Reports.

[23]  L. Price,et al.  Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Pooled Analysis of Randomized Clinical Trials , 2005, Stroke.

[24]  T. Nathaniel,et al.  Effect of antihypertensive medications on thrombolysis therapy and outcomes in acute ischemic stroke patients , 2019, Journal of clinical hypertension.

[25]  K. Mandl,et al.  Incidence and Patterns of Extended-Course Antibiotic Therapy in Patients Evaluated for Lyme Disease. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  J. Olivot,et al.  Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender: A Clinical Registry Study and Systematic Review , 2009, Stroke.

[27]  Jinlin Song,et al.  Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[28]  M. Hennerici,et al.  Gender Differences in Acute Ischemic Stroke: Etiology, Stroke Patterns and Response to Thrombolysis , 2009, Stroke.

[29]  F. Silver,et al.  Sex Differences in Stroke Care and Outcomes: Results From the Registry of the Canadian Stroke Network , 2005, Stroke.

[30]  Y. Kao Yang,et al.  Validity of a stroke severity index for administrative claims data research: a retrospective cohort study , 2016, BMC Health Services Research.

[31]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[32]  J. Biller,et al.  Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients. , 2014, Pediatric neurology.

[33]  Yea-Huei Kao Yang,et al.  Developing a stroke severity index based on administrative data was feasible using data mining techniques. , 2015, Journal of clinical epidemiology.

[34]  Shi-min Liu,et al.  Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator , 2018, Medicine.

[35]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[36]  W. Poewe,et al.  Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study , 2015, The Lancet Neurology.

[37]  L. Goldstein.  Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. , 1998, Stroke.

[38]  Yongjun Wang,et al.  Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke , 2017, PloS one.

[39]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[40]  J. Cha,et al.  Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke , 2018, BMC Neurology.

[41]  W. Hacke,et al.  Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials , 2014, BMJ : British Medical Journal.

[42]  W. Powers,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. , 2019, Stroke.

[43]  Tsong-Hai Lee,et al.  Establishment of electronic chart-based stroke registry system in a medical system in Taiwan. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.

[44]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association , 2018, Circulation.

[45]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[46]  V. Sharma,et al.  Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[47]  G. Peng,et al.  Nationwide “Hospital Emergent Capability Accreditation by Level-Stroke” Improves Stroke Treatment in Taiwan , 2017, Journal of stroke.

[48]  Manoel J. Teixeira,et al.  Meta-analysis of Vascular Imaging Features to Predict Outcome Following Intravenous rtPA for Acute Ischemic Stroke , 2016, Front. Neurol..

[49]  W. Chan,et al.  Sex and acute stroke presentation. , 2002, Annals of emergency medicine.

[50]  Ku-Chou Chang,et al.  Factors associated with prolonged hospital stay for acute stroke in Taiwan. , 2008, Acta neurologica Taiwanica.

[51]  J. Gargano,et al.  Sex Differences in Acute Stroke Care in a Statewide Stroke Registry , 2008, Stroke.

[52]  Sung-Chun Tang,et al.  Endovascular thrombectomy for acute ischemic stroke: A single-center experience in Taiwan. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[53]  P. Austin,et al.  Sex differences and similarities in the management and outcome of stroke patients. , 2000, Stroke.

[54]  E W Steyerberg,et al.  Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. , 1999, Journal of clinical epidemiology.

[55]  Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia , 2019, Cerebrovascular Diseases.